Anti-Tiragolumab ELISA Kit

Catalog No.

KAH72401

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. Tiragolumab has been pre-coated onto a microplate. Samples or standards are pipetted into microwells and anti-Tiragolumab will be captured by immobilized Tiragolumab. After washing away any unbound substances, a biotin-labeled Tiragolumab is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-Tiragolumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Anti-Tiragolumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

156.25 - 10,000 ng/mL

Sensitivity

10.11 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	5152.6	1166.1	282.1	5149.7	1342.1	325.3
Standard deviation	127.7	22.2	8.8	175.2	43.1	18.0
CV (%)	2.5	1.9	3.1	3.4	3.2	5.5

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃.

Alternative Names

MTIG-7192-A, MTIG-7192A, MTIG7192A, RG-6058, RO-7092284, RO7092284,CAS: 1918185-84-8

Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy., PMID:40374899

NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - dissection of IO- efficacy in NSCLC by longitudinal tracKing - protocol of a non-randomised, open-label, single-arm, phase II study., PMID:40147985

Staphylococcus aureus-specific TIGIT+ Treg are present in the blood of healthy subjects - a hurdle for vaccination?, PMID:39981298

Model-Informed Selection of the Recommended Phase 2 Dosage for Anti-TIGIT Immunotherapy Leveraging co-Expressed PD-1 Inhibitor Target Engagement., PMID:39921877

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study., PMID:39855251

Development and characterisation of [18F]TTDP, a novel T cell immunoglobulin and ITIM domain tracer, in humanised mice and non-human primates., PMID:39297961

The efficacy and safety of immunotherapy as first-line treatment for extensive-stage small cell lung cancer: evaluating based on reconstructed individual patient data., PMID:39026980

IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma., PMID:38861301

A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)., PMID:38858106

Implementation of a Three-Way Comparability Assessment for a Bioanalytical Anti-Drug Antibody Method., PMID:38637446

Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis., PMID:38623838

Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 study., PMID:38614072

Correction to: Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors., PMID:38556530

Structural insights into the unique pH-responsive characteristics of the anti-TIGIT therapeutic antibody Ociperlimab., PMID:38460520

Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors., PMID:38451273

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells., PMID:38418879

Targeting TIGIT for cancer immunotherapy: recent advances and future directions., PMID:38229100

Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors., PMID:38206370

Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)., PMID:38105505

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer., PMID:37976444

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer., PMID:37946136

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial., PMID:37768658

Acute liver failure following immune checkpoint inhibitors., PMID:37660741

Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis., PMID:37435087

Anti-TIGIT therapies for solid tumors: a systematic review., PMID:36933320

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno., PMID:36636263

Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer., PMID:35654050

Tiragolumab Results Cast Shadow on TIGIT Pipeline., PMID:35652612

Tiragolumab active in PD-L1+ NSCLC., PMID:35606416

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study., PMID:35576957

Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer., PMID:35292828

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity., PMID:33670993

ASCO 2020 non-small lung cancer (NSCLC) personal highlights., PMID:33456617

Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting., PMID:33271494

Tiragolumab Impresses in Multiple Trials., PMID:32576590

Document Download

Anti-Tiragolumab ELISA Kit.pdf